1
|
Dantal J, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, Del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra A, Hofbauer GFL, Kamar N, Pouteil-Noble C, Kanitakis J, Roux A, Decullier E, Euvrard S. Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results. J Clin Oncol 2018; 36:2612-2620. [PMID: 30016177 DOI: 10.1200/jco.2017.76.6691] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Purpose Transplant recipients who develop cutaneous squamous cell carcinomas are at high risk for multiple subsequent skin cancers. Sirolimus has been shown to reduce the occurrence of secondary skin cancers, but no study included a follow-up exceeding 2 years. We extended at 5 years the TUMORAPA randomized trial of sirolimus-based immunosuppressive regimen versus calcineurin inhibitor-based immunosuppression. Methods Kidney transplant recipients receiving calcineurin inhibitors who had at least one cutaneous squamous cell carcinoma were randomly assigned to receive sirolimus as a substitute for calcineurin inhibitors (n = 64) or to maintain their initial treatment (n = 56). The primary end point was survival free of squamous cell carcinoma at 5 years. Secondary end points included the occurrence of other skin cancers, renal function, patient and graft survival, and treatment tolerance. Results Survival free of cutaneous squamous cell carcinoma was significantly longer in the sirolimus group than in the calcineurin inhibitor group ( P = .007). In the sirolimus group, the number of patients with new skin cancers was significantly lower compared with the calcineurin inhibitor group: 22% versus 59% for squamous cell carcinomas ( P < .001), 34% versus 66% for other skin cancers ( P < .001), and 20% versus 37.5% for basal cell carcinomas ( P < .05). Kidney graft function, patients, and graft survival were similar in both groups. In the sirolimus group, the mean number of serious adverse effects per patient decreased from 1.16 during the first 2 years, to 0.83 between years 2 and 5. Conclusion In kidney transplant recipients with previous cutaneous squamous cell carcinomas, the antitumoral effect of conversion from calcineurin inhibitors to sirolimus was maintained at 5 years, and sirolimus tolerance was satisfactory.
Collapse
Affiliation(s)
- Jacques Dantal
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Emmanuel Morelon
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Lionel Rostaing
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Eric Goffin
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Anabelle Brocard
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Isabelle Tromme
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Nilufer Broeders
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Véronique Del Marmol
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Valérie Chatelet
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Anne Dompmartin
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Michèle Kessler
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Andreas Serra
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Günther F L Hofbauer
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Nassim Kamar
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Claire Pouteil-Noble
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Jean Kanitakis
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Adeline Roux
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Evelyne Decullier
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | - Sylvie Euvrard
- Jacques Dantal and Anabelle Brocard, Nantes University Hospital, Nantes; Emmanuel Morelon, Claire Pouteil-Noble, Jean Kanitakis, and Sylvie Euvrard, Hospices Civils de Lyon, Edouard Herriot Hospital Group; Adeline Roux and Evelyne Decullier, Hospices Civils de Lyon, Unité de Recherche Clinique, Lyon; Lionel Rostaing and Nassim Kamar, Toulouse University Hospital, Toulouse; Valérie Chatelet and Anne Dompmartin, University Hospital of Caen, Caen; Michèle Kessler, University Hospital of Nancy, Vandœuvre-lès-Nancy, France; Eric Goffin and Isabelle Tromme, St Luc University Hospital, Woluwe-Saint-Lambert; Nilufer Broeders and Véronique del Marmol, Université Libre de Bruxelles, Bruxelles, Belgium; and Andreas Serra and Günther F.L. Hofbauer, Zürich University Hospital, Zürich, Switzerland
| | | |
Collapse
|
2
|
Knol AC, Vallée A, Herbreteau G, Nguyen JM, Varey E, Gaultier A, Théoleyre S, Saint-Jean M, Peuvrel L, Brocard A, Quéreux G, Khammari A, Denis MG, Dréno B. Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline. Exp Dermatol 2018; 25:783-8. [PMID: 27194447 DOI: 10.1111/exd.13065] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2016] [Indexed: 12/12/2022]
Abstract
Circulating tumor DNA is a promising non-invasive tool for cancer monitoring. The main objective of our work was to investigate the relationship between mutant BRAF DNA in plasma and clinical response. Thirty-eight stage IV patients with a V600 mutated BRAF melanoma were included prior to any treatment. DNA was extracted from plasma and mutant DNA was detected using the amplification-refractory mutation system method. Before the beginning of any treatment, the corresponding BRAF mutation was detected in 29 of the 38 tested plasma samples (76.3% positive per cent agreement). We observed a strong correlation between the presence of circulating mutated DNA and overall survival (OS; P=.02), and with the number of metastatic sites (P=.01). The presence of circulating mutated DNA was also strongly correlated with serum LDH activity (P<.01) and S100 protein concentration (P<.01). Finally, seven patients presented discordant BRAF status in different tumor sites. In all these patients, the test performed on ctDNA was positive, suggesting that ctDNA analysis might be less sensitive to tumor heterogeneity. Altogether, these results suggest that plasmatic mutant BRAF DNA is a prognostic factor of OS, correlated with tumor burden. In addition, it represents an interesting alternative source of DNA to detect BRAF mutations before treatment.
Collapse
Affiliation(s)
- Anne C Knol
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France
| | - Audrey Vallée
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Laboratoire de Biochimie et Plateforme de Génétique des Cancers, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | - Guillaume Herbreteau
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Laboratoire de Biochimie et Plateforme de Génétique des Cancers, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | - Jean-Michel Nguyen
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,SEB-PIMESP, CHU Nantes, Nantes Cedex 01, France
| | - Emilie Varey
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Unité de Cancéro-Dermatologie-CIC biothérapie INSERM 0503, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | | | - Sandrine Théoleyre
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Laboratoire de Biochimie et Plateforme de Génétique des Cancers, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | - Mélanie Saint-Jean
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Unité de Cancéro-Dermatologie-CIC biothérapie INSERM 0503, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | - Lucie Peuvrel
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Unité de Cancéro-Dermatologie-CIC biothérapie INSERM 0503, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | - Anabelle Brocard
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Unité de Cancéro-Dermatologie-CIC biothérapie INSERM 0503, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | - Gaëlle Quéreux
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Unité de Cancéro-Dermatologie-CIC biothérapie INSERM 0503, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | - Amir Khammari
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Unité de Cancéro-Dermatologie-CIC biothérapie INSERM 0503, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | - Marc G Denis
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France.,Laboratoire de Biochimie et Plateforme de Génétique des Cancers, CHU Hôtel-Dieu, Nantes Cedex 01, France
| | - Brigitte Dréno
- CRCNA, , INSERM U892, CNRS 6299, Nantes Cedex 01, France. .,Unité de Cancéro-Dermatologie-CIC biothérapie INSERM 0503, CHU Hôtel-Dieu, Nantes Cedex 01, France.
| |
Collapse
|
3
|
Rouzaud C, Chosidow O, Brocard A, Fraitag S, Scemla A, Anglicheau D, Bouaziz JD, Dupin N, Bougnoux ME, Hay R, Lortholary O, Lanternier F. Severe dermatophytosis in solid organ transplant recipients: A French retrospective series and literature review. Transpl Infect Dis 2018; 20. [PMID: 29094463 DOI: 10.1111/tid.12799] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 07/09/2017] [Indexed: 11/29/2022]
Abstract
OBJECTIVE Severe dermatophytosis is described in immunocompromised patients with defective cellular immunity. We report here a large series and a literature review of severe dermatophytosis in solid-organ transplant (SOT) recipients. METHOD The data main source was a national French retrospective study of severe dermatophytosis in SOT recipients between 2010 and 2016. Inclusion criteria were the presence of dermatophytes in skin culture and 1 severity criteria: dermal invasion by dermatophytes (invasive dermatophytosis) or involvement of at least two body sites or >10% of body surface area (extensive dermatophytosis). RESULTS A total of 12 patients were included (8 men, median age of 56 years [range: 33-71]). Of the 12 patients, 10 underwent kidney transplantation. The median time from transplantation to severe dermatophytosis diagnosis was 16 months [range: 2-94]. Clinical signs of superficial dermatophytosis were present in 8/12 patients before the emergence of severe dermatophytosis. Nine patients had invasive forms and three extensive ones, and nodules of the lower extremities were found in eight. Trichophyton rubrum was isolated in 11 cases. First-line treatment was terbinafine (7/12), posaconazole (3/12), or topical treatment alone (2/12). Immunosuppressive therapy was reduced in 3 patients because of associated infections. Complete response was obtained for 3/3 and 5/9 patients with extensive or invasive forms, respectively, after a median treatment's duration of 2.5 [range: 1.5-5] months and 7.5 months [range: 4-12]. Unrelated deaths (n = 2) and graft function impairment (n = 3) occurred. CONCLUSION Severe dermatophytosis is a late complication in SOT recipients presenting with lower limb nodules, which might be prevented by prompt treatment of superficial dermatophytosis.
Collapse
Affiliation(s)
- Claire Rouzaud
- Infectious Diseases and Tropical Medicine Department, Necker-Pasteur Infectious Diseases Center, Necker-Enfants malades Hospital, AP-HP, IHU Imagine, Paris Descartes University, Paris, France
| | - Olivier Chosidow
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Paris-Est Créteil University, Créteil, France
| | - Anabelle Brocard
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - Sylvie Fraitag
- Department of Pathology, Necker-Enfants malades Hospital, AP-HP, Paris Descartes University, Paris, France
| | - Anne Scemla
- Department of Nephrology-Transplantation, Necker-Enfants malades Hospital, AP-HP, Paris Descartes Sorbonne Paris Cité University, RTRS Centaure, Labex Transplantex, Paris, France
| | - Dany Anglicheau
- Paris Descartes University, Department of Nephrology-Transplantation, Necker-Enfants malades Hospital, AP-HP, Paris, France
| | | | - Nicolas Dupin
- Department of Dermatology, Cochin Tarnier Hospital, AP-HP, Paris Descartes University, Paris, France
| | - Marie-Elisabeth Bougnoux
- Department of Mycology, Necker-Enfants malades Hospital, AP-HP, Paris Descartes University, Paris, France
| | - Roderick Hay
- Dermatology Department, King's College Hospital NHS Trust, London, UK
| | - Olivier Lortholary
- Infectious Diseases and Tropical Medicine Department, Necker-Pasteur Infectious Diseases Center, Necker-Enfants malades Hospital, AP-HP, IHU Imagine, Paris Descartes University, Paris, France.,National Reference Center for Invasive Mycoses and Antifungals Molecular Mycology Unit, CNRS URA3012, Institut Pasteur, Paris, France
| | - Fanny Lanternier
- Infectious Diseases and Tropical Medicine Department, Necker-Pasteur Infectious Diseases Center, Necker-Enfants malades Hospital, AP-HP, IHU Imagine, Paris Descartes University, Paris, France.,National Reference Center for Invasive Mycoses and Antifungals Molecular Mycology Unit, CNRS URA3012, Institut Pasteur, Paris, France
| | | |
Collapse
|
4
|
Brocard A, Knol AC, Bossard C, Denis MG, Quéreux G, Saint-Jean M, Peuvrel L, Khammari A, Blancho G, Dantal J, Dréno B. Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients. Acta Derm Venereol 2017; 97:483-488. [PMID: 27868139 DOI: 10.2340/00015555-2568] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The aims of this study were to determine the clinical and histological characteristics of melanoma in transplant recipients, the mutation profile (BRAF, NRAS and c-KIT genes), and the immune tolerance of the tumour microenvironment by immunohistochemical study of the expression of indoleamine 2,3-dioxygenase (IDO), PD1, PD-L1, CD8 and FoxP3. The study population comprised patients who had undergone a renal transplant in Nantes University Hospital who developed post-transplantation melanoma. Twenty cases of melanoma out of 4,663 transplant recipients were studied. The results differed from the usual data with respect to melanoma site: 40% were located on the face and were of the malignant lentigo type. The mutation profile was concordant with that of the immunocompetent population. IDO was expressed in all the sections tested, while CD8, FoxP3, PD1 and PD-L1 were poorly expressed. This reflected a highly immunodepressed tumour environment, raising the question of the inductive role of IDO on tumour immune tolerance in patients presenting with long-term immunodepression.
Collapse
Affiliation(s)
- Anabelle Brocard
- Department of Dermatology, Nantes University Hospital, INSERM, 892, FR-44000 Nantes, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ducroux E, Martin C, Bouwes Bavinck JN, Decullier E, Brocard A, Westhuis-van Elsäcker ME, Lebbé C, Francès C, Morelon E, Legendre C, Joly P, Kanitakis J, Jullien D, Euvrard S, Dantal J. Risk of Aggressive Skin Cancers After Kidney Retransplantation in Patients With Previous Posttransplant Cutaneous Squamous Cell Carcinomas: A Retrospective Study of 53 Cases. Transplantation 2017; 101:e133-e141. [PMID: 28099404 PMCID: PMC7228575 DOI: 10.1097/tp.0000000000001644] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Revised: 12/05/2016] [Accepted: 12/09/2016] [Indexed: 12/16/2022]
Abstract
BACKGROUND The course of skin cancer after retransplantation in organ-transplant recipients who have already developed posttransplant skin cancer has not been assessed. METHODS This retrospective multicentric study included 53 patients with a history of cutaneous squamous cell carcinoma (SCC) after a first kidney transplantation who received a second kidney transplantation. The primary endpoint was the occurrence of aggressive cutaneous SCC after the second transplantation. Secondary endpoints included the course of skin cancers over 3 periods (first transplantation, return to dialysis, second transplantation), the time to occurrence, and risk factors for aggressive SCC after retransplantation. RESULTS The first SCC developed in 47 patients with a functional graft and in 6 after return to dialysis. After the first transplantation, 17 (33.3%) patients developed SCC in dialysis and 39 (73.6%) after the second transplantation, respectively. Twenty aggressive SCC developed over the study period. They occurred in 14 (26.4%) patients after retransplantation vs 5 (9.4%) after the first transplantation with a median delay of 50 months and were responsible for 5 deaths. Fair skin type, multiple tumors before retransplantation, treatment with azathioprine, T cell-depleting antibodies, and delayed revision of immunosuppression were associated with an increased risk of aggressive cutaneous SCC after retransplantation. CONCLUSIONS Candidates to retransplantation with a history of posttransplant SCC have a high risk of aggressive SCC. Our data suggest that the risk could be reduced by a tailored immunosuppression. A wait period may be required depending on the clinicopathological characteristics of the previous SCC and discussed on an individual patient basis.
Collapse
Affiliation(s)
- Emilie Ducroux
- 1 Department of Dermatology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France. 2 Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands. 3 Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Lyon, France. 4 Université de Lyon, Laboratoire Santé Individu Société, Lyon, France. 5 Department of Dermatology, Nantes University Medical Center, Nantes, France. 6 Department of Dermatology, Saint Louis Hospital, APHP, University Paris VII, Paris, France. 7 Department of Dermatology, Tenon Hospital, APHP, University Paris VI, Paris, France. 8 Department of Transplantation and Nephrology, Edouard Herriot Hospital, Université de Lyon, Lyon, France. 9 Department of Nephrology-Transplantation, Necker Hospital, APHP, Paris, France. 10 Department of Dermatology, Charles-Nicolle University Medical Center, Rouen, France. 11 Department of Renal Medicine and Transplantation, Nantes University Medical Center, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Peuvrel L, Cassecuel J, Bernier C, Joubert A, Saint-Jean M, Quereux G, Le Moigne M, Brocard A, Khammari A, Dréno B. Toxican : un outil à d’aide à la cotation des toxicités cutanées des traitements anticancéreux au quotidien. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Quéreux G, Josselin N, Saint-Jean M, Peuvrel L, Brocard A, Dréno B. Exceptional Association of Syringotropic Mycosis Fungoides with Chronic Lymphocytic Leukaemia. Acta Derm Venereol 2016; 96:263-4. [PMID: 26258873 DOI: 10.2340/00015555-2199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
MESH Headings
- Aged
- Biomarkers, Tumor/analysis
- Biopsy
- Eccrine Glands/pathology
- Eccrine Glands/virology
- Female
- Herpesvirus 4, Human/isolation & purification
- Humans
- Immunohistochemistry
- Leukemia, Lymphocytic, Chronic, B-Cell/complications
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/virology
- Mycosis Fungoides/complications
- Mycosis Fungoides/pathology
- Mycosis Fungoides/virology
- Predictive Value of Tests
- Skin Neoplasms/complications
- Skin Neoplasms/diagnosis
- Skin Neoplasms/virology
Collapse
Affiliation(s)
- Gaëlle Quéreux
- Skin Cancer Unit, Nantes University Hospital, INSERM, 892, FR-44093 Nantes, France. ,
| | | | | | | | | | | |
Collapse
|
8
|
Frenard C, Peuvrel L, Brocard A, Saint-Jean M, Moreau A, Dreno B, Quéreux G. Dramatic response of an inoperable Merkel cell carcinoma with imatinib. JAAD Case Rep 2016; 2:16-8. [PMID: 27051816 PMCID: PMC4809439 DOI: 10.1016/j.jdcr.2015.10.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Affiliation(s)
- Cecile Frenard
- Skin Cancer Unit, Nantes University Hospital, Cedex, France
| | - Lucie Peuvrel
- Skin Cancer Unit, Nantes University Hospital, Cedex, France
| | | | | | - Anne Moreau
- Department of Pathology, Hotel Dieu, Cedex, France
| | - Brigitte Dreno
- Skin Cancer Unit, Nantes University Hospital, Cedex, France
| | - Gaelle Quéreux
- Skin Cancer Unit, Nantes University Hospital, Cedex, France
| |
Collapse
|
9
|
Frenard C, Peuvrel L, Saint-Jean M, Brocard A, NGuyen JM, Khammari A, Quereux G, Dreno B. Étude de la survenue de métastases cérébrales sous traitement par ipilimumab de mélanomes métastatiques. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Knol A, Vallée A, Varey E, Nguyen JM, Herbreteau G, Théoleyre S, Saint-Jean M, Quéreux G, Peuvrel L, Brocard A, Khammari A, Denis M, Dréno B. Détection de mutations de BRAF dans le plasma de patients atteints de mélanome métastatique. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Martin C, Bouwes Bavinck JN, Decullier E, Brocard A, Von Elsäcker M, Lebbé C, Francès C, Morelon E, Glotz D, Legendre C, Joly P, Ducroux E, Kanitakis J, Euvrard S, Dantal J. Étude de 62 greffés rénaux ayant eu au moins un carcinome épidermoïde après greffe en cas de retransplantation. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Le Naour S, Saint-Jean M, Peuvrel L, Quéreux G, Brocard A, Dréno B. Premier cas d’érythème polymorphe sous anti-PD-1 (nivolumab). Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Peuvrel L, Quéreux G, Saint-Jean M, Brocard A, Nguyen JM, Khammari A, Knol AC, Varey E, Dréno B. Profile of vemurafenib-induced severe skin toxicities. J Eur Acad Dermatol Venereol 2015; 30:250-7. [PMID: 26524690 DOI: 10.1111/jdv.13443] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Accepted: 09/04/2015] [Indexed: 01/10/2023]
Abstract
BACKGROUND Vemurafenib, a BRAF inhibitor, is commonly associated with skin toxicity. The impact of severe forms is unknown. OBJECTIVE To determine the rate of permanent vemurafenib discontinuation due to grade 3-4 skin toxicity, features of these toxicities, their recurrence rate after a switch to dabrafenib and their impact on overall survival. METHODS Retrospective cohort study of 131 patients treated with vemurafenib for melanoma between November 2010 and December 2014. Data on skin toxicities, the need for vemurafenib adjustment and the impact of switching to dabrafenib were collected. Regarding survival analysis, a conditional landmark analysis was performed to correct lead-time bias. RESULTS Among the 131 vemurafenib-treated patients, 26% developed grade 3-4 skin toxicity. Forty-four percent of them permanently discontinued their treatment, mainly due to rash and classic skin adverse reactions (Steven-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms). Conversely, photosensitivity and carcinomas rarely required treatment adjustment. Grade 3-4 rashes were associated with clinical or biological abnormalities in 94% of patients. Among the 10 patients who subsequently switched to dabrafenib, skin toxicity recurred only in one patient. Overall survival was significantly prolonged in case of severe skin toxicity emerging within the first 4 (P = 0.014) and 8 weeks (P = 0.038) on vemurafenib, with only a trend at 12 weeks (P = 0.052). Median overall survival was also prolonged in case of severe rash. CONCLUSION In this study, vemurafenib was continued in 56% of patients with grade 3-4 skin toxicity, which was associated with prolonged overall survival when emerging within the first 4 and 8 weeks of treatment. While developing severe skin adverse reactions permanently contraindicates vemurafenib use, other rashes should lead to retreatment attempts with dose reduction. In case of recurrence, dabrafenib seems to be an interesting option. For other skin toxicities, including photosensitivity and cutaneous carcinoma, treatment adjustment is usually not needed.
Collapse
Affiliation(s)
- L Peuvrel
- Department of Dermatology, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| | - G Quéreux
- Department of Dermatology, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| | - M Saint-Jean
- Department of Dermatology, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| | - A Brocard
- Department of Dermatology, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| | - J M Nguyen
- Department of Epidemiology and Biostatistics, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| | - A Khammari
- Department of Dermatology, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| | - A C Knol
- Department of Dermatology, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| | - E Varey
- Department of Dermatology, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| | - B Dréno
- Department of Dermatology, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| |
Collapse
|
14
|
Frenard C, Peuvrel L, Jean MS, Brocard A, Knol AC, Nguyen JM, Khammari A, Quereux G, Dreno B. Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. J Neurooncol 2015; 126:355-60. [PMID: 26511495 DOI: 10.1007/s11060-015-1977-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Accepted: 10/25/2015] [Indexed: 11/30/2022]
Abstract
UNLABELLED Ipilimumab is a monoclonal antibody blocking the inhibitory molecule CTLA4 expressed by activated T lympocytes, used for the treatment of metastatic melanoma. Recent studies have shown its potential efficacy on brain metastases. OBJECTIVES To assess the development of brain metastases under ipilimumab and identify clinical, histological or evolving criteria related to the appearance of these metastases. A retrospective study was conducted in 52 patients treated with 4 cycles of ipilimumab 3 mg/kg every 3 weeks for unresectable stage III or stage IV melanoma between January 2011 and July 2013 in a Department of Dermato-Oncology. As no data has been find in the literature, the results were compared to our other cohort of patients treated with vemurafenib during the same period. Ten patients (21.7 %) developed brain metastases under ipilimumab in a median time of 6.58 months after treatment initiation. The multivariate analysis showed a lower rate of brain metastases in patients with acral lentiginous melanoma and melanoma of unknown primary site. The median survival after diagnosis of brain metastases was of 2.5 months. There was no significant difference with vemurafenib-treated patients in terms of incidence rate of brain metastasis, time of development and survival after diagnosis of cerebral metastases. This was the first study focused on the development of brain metastases under treatment with ipilimumab 3 mg/kg. Although ipilimumab is used for the treatment of brain metastases, it paradoxically did not seem to reduce the risk of developing brain metastases.
Collapse
Affiliation(s)
- C Frenard
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - L Peuvrel
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - M Saint Jean
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - A Brocard
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - A C Knol
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - J M Nguyen
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - A Khammari
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - G Quereux
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France
| | - B Dreno
- Department of dermatology, Skin Cancer Unit, Nantes University Hospital, INSERM 892, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France.
| |
Collapse
|
15
|
Munch M, Peuvrel L, Brocard A, Saint Jean M, Khammari A, Dreno B, Quereux G. Early-Onset Vemurafenib-Induced DRESS Syndrome. Dermatology 2015; 232:126-8. [PMID: 26418832 DOI: 10.1159/000439272] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Accepted: 08/05/2015] [Indexed: 11/19/2022] Open
Abstract
Vemurafenib is a BRAF inhibitor indicated in metastatic or unresectable melanoma in patients with BRAF mutations. Vemurafenib is frequently toxic, but the toxicity is often not serious. The third case of vemurafenib-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is reported herein. The case is unusual in that the onset was early, with symptoms emerging as of day 8 of treatment. Treatment of DRESS syndrome is not currently based on precise recommendations, but systemic corticosteroid therapy is effective in serious cases. Severe toxidermias under vemurafenib are exceptional; immediate discontinuation of treatment upon diagnosis is imperative. Switching from vemurafenib to dabrafenib then seems to constitute an interesting therapeutic alternative, since its efficacy is the same but with fewer cutaneous adverse reactions. This case highlights the importance of awareness of the risk of DRESS syndrome associated with vemurafenib and monitoring for warning signs from treatment initiation.
Collapse
Affiliation(s)
- Marion Munch
- Dermatology, Inserm 892, Nantes University Hospital, Nantes, France
| | | | | | | | | | | | | |
Collapse
|
16
|
Le Moigne M, Saint-Jean M, Jirka A, Quéreux G, Peuvrel L, Brocard A, Gaultier A, Khammari A, Darmaun D, Dréno B. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management. Support Care Cancer 2015; 24:1689-95. [PMID: 26416491 DOI: 10.1007/s00520-015-2932-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Accepted: 08/31/2015] [Indexed: 11/12/2022]
Abstract
PURPOSE Whereas vismodegib is effective in the treatment of locally advanced/metastatic basal cell carcinoma, dysgeusia and weight loss are common side effects of such treatment. The main objective of this study was to monitor the nutritional status of vismodegib-treated patients. Secondary objective was to assess the incidence of dysgeusia and the benefit of early nutritional management. METHODS This prospective study included all patients who started vismodegib between October 2011 and May 2013 at Nantes University Hospital. Prior to July 2012, patients treated with vismodegib had not received any specific nutritional management (Historical cohort). Body weight and presence of dysgeusia were recorded monthly. Patients treated after July 2012 (Nutrition cohort) were evaluated by a physician of the Nutrition Support Unit and received dietary counseling at vismodegib initiation. A standardized nutritional management protocol was initiated in case of significant weight loss. RESULTS Forty-five patients (21 and 24 in the Nutrition and Historical cohort, respectively) were enrolled. In the Nutrition cohort, five patients (24 %) were undernourished at vismodegib initiation, and the 6-month cumulative incidence of dysgeusia was 71 %. Eight patients (38 %) and 13 patients (54 %) had a weight loss greater than 5 % in the Nutrition and Historical cohort, respectively (p = 0.3727). CONCLUSION The results of this pilot study suggest the benefit of early nutritional screening. The potential benefit of nutritional support in this setting warrants further investigation.
Collapse
Affiliation(s)
- Marie Le Moigne
- Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Nantes, France.,Inserm, UMR 892, CIC Biotherapy Inserm 0503, Nantes, France
| | - Mélanie Saint-Jean
- Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Nantes, France.,Inserm, UMR 892, CIC Biotherapy Inserm 0503, Nantes, France
| | - Adam Jirka
- Nutrition Support Team IMAD, DHU 2020, University Hospital Hôtel-Dieu, Nantes, France
| | - Gaëlle Quéreux
- Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Nantes, France.,Inserm, UMR 892, CIC Biotherapy Inserm 0503, Nantes, France
| | - Lucie Peuvrel
- Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Nantes, France.,Inserm, UMR 892, CIC Biotherapy Inserm 0503, Nantes, France
| | - Anabelle Brocard
- Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Nantes, France.,Inserm, UMR 892, CIC Biotherapy Inserm 0503, Nantes, France
| | | | - Amir Khammari
- Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Nantes, France.,Inserm, UMR 892, CIC Biotherapy Inserm 0503, Nantes, France
| | - Dominique Darmaun
- Nutrition Support Team IMAD, DHU 2020, University Hospital Hôtel-Dieu, Nantes, France
| | - Brigitte Dréno
- Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Nantes, France. .,Inserm, UMR 892, CIC Biotherapy Inserm 0503, Nantes, France. .,Dermato-cancerology Unit, University Hospital Hôtel-Dieu, Place Alexis Ricordeau, 44093, Cedex 01, France.
| |
Collapse
|
17
|
Khammari A, Nguyen JM, Saint-Jean M, Knol AC, Pandolfino MC, Quereux G, Brocard A, Peuvrel L, Saiagh S, Bataille V, Limacher JM, Dreno B. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. Cancer Immunol Immunother 2015; 64:805-15. [PMID: 25846669 PMCID: PMC11029588 DOI: 10.1007/s00262-015-1691-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Accepted: 03/23/2015] [Indexed: 01/08/2023]
Abstract
Tumor immune escape has recently been shown to be related to the development of an immune tolerance state of the microenvironment. Cytokines activating the immune system such as IFN-γ can be used to reverse the immune escape and thus to potentiate the efficacy of immunotherapy. A clinical study was conducted in 18 stage IIIc/IV melanoma patients treated with tumor-infiltrating lymphocytes (TILs) in combination with intratumoral TG1042 injection (adenovirus expressing IFN-γ). The primary objective was to investigate the safety of treatment. Secondary objectives were to study the clinical response and translational research. The treatment was well tolerated. Among the 13 patients evaluable for tumor response, 38.5% had an overall objective response (OOR = CR + PR) and disease control rate (DCR = CR + PR + S) of 46%. The clinical response of the 37 targeted lesions led to an OOR of 51% and a DCR of 75%. Translational research on predictive markers did not significantly differ between responder and non-responder patients. However, specifically regarding injected lesions, the clinical response correlated with CD3-/CD56+ NK cells which could be activated by TG1042. Further larger studies of this combined immunotherapy are needed to confirm our findings. Intralesional TG1042 combined with antigen-selected TILs should be discussed.
Collapse
Affiliation(s)
- Amir Khammari
- Dermato-Oncology Department, Nantes Hospital, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
- Cancer Research Center Nantes-Angers (Inserm U892, CNRS 6299), 9 Quai Moncousu, 44093 Nantes Cedex 1, France
| | - Jean-Michel Nguyen
- Cancer Research Center Nantes-Angers (Inserm U892, CNRS 6299), 9 Quai Moncousu, 44093 Nantes Cedex 1, France
- Biostatistic Department (PIMESP), Hôpital St Jacques - CHU Nantes, 44093 Nantes, France
| | - Melanie Saint-Jean
- Dermato-Oncology Department, Nantes Hospital, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
- Cancer Research Center Nantes-Angers (Inserm U892, CNRS 6299), 9 Quai Moncousu, 44093 Nantes Cedex 1, France
| | - Anne-Chantal Knol
- Cancer Research Center Nantes-Angers (Inserm U892, CNRS 6299), 9 Quai Moncousu, 44093 Nantes Cedex 1, France
| | - Marie-Christine Pandolfino
- Cancer Research Center Nantes-Angers (Inserm U892, CNRS 6299), 9 Quai Moncousu, 44093 Nantes Cedex 1, France
- Cell and Gene Therapy Unit (UTCG), Nantes Hospital, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
| | - Gaelle Quereux
- Dermato-Oncology Department, Nantes Hospital, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
- Cancer Research Center Nantes-Angers (Inserm U892, CNRS 6299), 9 Quai Moncousu, 44093 Nantes Cedex 1, France
| | - Anabelle Brocard
- Dermato-Oncology Department, Nantes Hospital, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
- Cancer Research Center Nantes-Angers (Inserm U892, CNRS 6299), 9 Quai Moncousu, 44093 Nantes Cedex 1, France
| | - Lucie Peuvrel
- Dermato-Oncology Department, Nantes Hospital, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
- Cancer Research Center Nantes-Angers (Inserm U892, CNRS 6299), 9 Quai Moncousu, 44093 Nantes Cedex 1, France
| | - Soraya Saiagh
- Cell and Gene Therapy Unit (UTCG), Nantes Hospital, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
| | - Vincent Bataille
- Transgene SA, Boulevard Gonthier d’Andernach, CS80166, 67405 Illkirch-Graffenstaden, France
| | - Jean-Marc Limacher
- Transgene SA, Boulevard Gonthier d’Andernach, CS80166, 67405 Illkirch-Graffenstaden, France
| | - Brigitte Dreno
- Dermato-Oncology Department, Nantes Hospital, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
- Cancer Research Center Nantes-Angers (Inserm U892, CNRS 6299), 9 Quai Moncousu, 44093 Nantes Cedex 1, France
- Cell and Gene Therapy Unit (UTCG), Nantes Hospital, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
| |
Collapse
|
18
|
Haim H, Dutartre H, Saint-Jean M, Brocard A, Peuvrel L, Quéreux G, Dréno B. [Diagnostic pitfalls of solar urticaria]. Ann Dermatol Venereol 2015; 142:299-300. [PMID: 25813186 DOI: 10.1016/j.annder.2014.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Revised: 11/09/2014] [Accepted: 12/29/2014] [Indexed: 11/30/2022]
Affiliation(s)
- H Haim
- Service de dermatologie, CHU Hôtel Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France.
| | - H Dutartre
- Service de dermatologie, CHU Hôtel Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France
| | - M Saint-Jean
- Service de dermatologie, CHU Hôtel Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France
| | - A Brocard
- Service de dermatologie, CHU Hôtel Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France
| | - L Peuvrel
- Service de dermatologie, CHU Hôtel Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France
| | - G Quéreux
- Service de dermatologie, CHU Hôtel Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France
| | - B Dréno
- Service de dermatologie, CHU Hôtel Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France
| |
Collapse
|
19
|
Kogge A, Volteau C, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Renaut JJ, Dréno B, Quéreux G. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients. Acta Derm Venereol 2015; 95:72-7. [PMID: 24806744 DOI: 10.2340/00015555-1886] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Since the approval of vorinostat for the treatment of refractory cutaneous epidermotropic T-cell lymphoma (CTCL) in 2006, very little data about this treatment have been published. The aim of this retrospective study was to assess the efficacy and safety of vorinostat in patients with CTCL treated between 2007 and 2013 in our department. Fifteen patients (median age 64 years) were included: 9 with Sézary syndrome and 6 with mycosis fungoides. They were all in progression and the median number of systemic treatments previously administered was 3 (range 1-7). With vorinostat treatment, the best response was partial remission in 5 patients (33%) and stabilization in 4 patients (27%). Six patients experienced disease progression. The mean time to response and response duration were 70 (range 31-140) and 300 days (range 157-663), respectively. The most frequent adverse events were asthenia, weight loss, nausea and anaemia. Vorinostat could be a therapeutic alternative for CTCL after treatment failure.
Collapse
Affiliation(s)
- Anne Kogge
- Department of Dermato-Oncology, Nantes University Hospital, INSERM 892, 44093 Nantes, France
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Guillet A, Brocard A, Bach Ngohou K, Graveline N, Leloup AG, Ali D, Nguyen JM, Loirat MJ, Chevalier C, Khammari A, Dreno B. Verneuil's disease, innate immunity and vitamin D: a pilot study. J Eur Acad Dermatol Venereol 2014; 29:1347-53. [PMID: 25512084 DOI: 10.1111/jdv.12857] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2014] [Accepted: 10/17/2014] [Indexed: 01/20/2023]
Abstract
BACKGROUND Verneuil's disease is a chronic inflammatory skin disease of the follicles in apocrine glands rich area of the skin (axillary, inguinal, anogenital) and is associated with a deficient skin innate immunity. It is characterized by the occurrence of nodules, abscesses, fistulas, scars. Recently, vitamin D has been shown to stimulate skin innate immunity. OBJECTIVE The primary objective of the study was to assess whether Verneuil's disease was associated with vitamin D deficiency. The secondary objective was to determine whether vitamin D supplementation could improve inflammatory lesions. METHODS First, 25(OH) vitamin D3 serum levels in patients with Verneuil's disease followed at Nantes University Hospital were compared to those of healthy donors from the French Blood Bank. Then, a pilot study was conducted in 14 patients supplemented with vitamin D according to their vitamin D level at baseline at months 3 and 6. The endpoints at 6 months were decreased by at least 20% in the number of nodules and in the frequency of flare-ups. RESULTS Twenty-two patients (100%) had vitamin D deficiency (level <30 ng/mL) of whom 36% were severely deficient (level <10 ng/mL), having correlation with the disease severity (P = 0.03268) vs. 20 controls with vitamin D deficiency (91%) of whom 14% were severely deficient. In 14 patients, the supplementation significantly decreased the number of nodules at 6 months (P = 0.01133), and the endpoints were achieved in 79% of these patients. A correlation between the therapeutic success and the importance of the increase in vitamin D level after supplementation was observed (P = 0.01099). CONCLUSION Our study shows that Verneuil's disease is associated with a major vitamin D deficiency, correlated with the disease severity. It suggests that vitamin D could significantly improve the inflammatory nodules, probably by stimulating the skin innate immunity. A larger randomized study is needed to confirm these findings.
Collapse
Affiliation(s)
- A Guillet
- Service de Dermato-Cancérologie, CHU Hôtel-Dieu, Nantes, France
| | - A Brocard
- Service de Dermato-Cancérologie, CHU Hôtel-Dieu, Nantes, France
| | - K Bach Ngohou
- Laboratoire de radio-immunologie, CHU Hôtel Dieu, Nantes, France
| | - N Graveline
- Laboratoire de radio-immunologie, CHU Hôtel Dieu, Nantes, France
| | - A-G Leloup
- Laboratoire de radio-immunologie, CHU Hôtel Dieu, Nantes, France
| | - D Ali
- Laboratoire de radio-immunologie, CHU Hôtel Dieu, Nantes, France
| | - J-M Nguyen
- Service de santé publique PIMESP, Hôpital Saint Jacques, Nantes, France
| | - M-J Loirat
- Etablissement Français du Sang, CHU Hôtel Dieu, Nantes, France
| | - C Chevalier
- Etablissement Français du Sang, CHU Hôtel Dieu, Nantes, France
| | - A Khammari
- Service de Dermato-Cancérologie, CHU Hôtel-Dieu, Nantes, France
| | - B Dreno
- Service de Dermato-Cancérologie, CHU Hôtel-Dieu, Nantes, France
| |
Collapse
|
21
|
Munch M, Quereux G, Peuvrel L, Brocard A, Saint Jean M, Dreno B, Khammari A. Apparition rare d’un DRESS syndrome sous vémurafénib. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Guillet A, Brocard A, Bach K, Chevalier C, Nguyen JM, Graveline N, Leloupp AG, Loirat MJ, Khammari A, Dreno B. Déficit en vitamine D et supplémentation dans la maladie de Verneuil : étude pilote. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Jirka A, Saint-Jean M, Le Moigne M, Quéreux G, Peuvrel L, Brocard A, Khammari A, Darmaun D, Dréno B. P273: Dysgueusie et dénutrition au cours des traitements par le vismodegib : effet d’une prise en charge nutritionnelle. NUTR CLIN METAB 2014. [DOI: 10.1016/s0985-0562(14)70915-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
24
|
Frenard C, Peuvrel L, Brocard A, Saint Jean M, Dreno B, Quereux G. Réponse spectaculaire d’un carcinome de Merkel sous imatinib. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
25
|
Quereux G, Brocard A, Peuvrel L, Saint-Jean M, Wylomanski S, Bouquin R, Vaucel E, Dréno B. Mélanomes vaginaux et vulvaires métastatiques : intérêt de l’ipilimumab ? Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
26
|
Haim H, Dutartre H, Saint-Jean M, Brocard A, Peuvrel L, Querreux G, Dréno B. Quand les habits aident au diagnostic d’une photodermatose rare. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Haim H, Hurault M, Renaud JJ, Saint-Jean M, Brocard A, Peuvrel L, Quéreux G, Dréno B. Acneiform rash: an unusual presentation of epithelioid haemangioma. J Eur Acad Dermatol Venereol 2014; 30:470-2. [PMID: 25376982 DOI: 10.1111/jdv.12852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- H Haim
- Department of Oncodermatology, CHU Hôtel Dieu, Nantes, France
| | - M Hurault
- Department of Oncodermatology, CHU Hôtel Dieu, Nantes, France
| | - J J Renaud
- Department of Oncodermatology, CHU Hôtel Dieu, Nantes, France
| | - M Saint-Jean
- Department of Oncodermatology, CHU Hôtel Dieu, Nantes, France
| | - A Brocard
- Department of Oncodermatology, CHU Hôtel Dieu, Nantes, France
| | - L Peuvrel
- Department of Oncodermatology, CHU Hôtel Dieu, Nantes, France
| | - G Quéreux
- Department of Oncodermatology, CHU Hôtel Dieu, Nantes, France
| | - B Dréno
- Department of Oncodermatology, CHU Hôtel Dieu, Nantes, France
| |
Collapse
|
28
|
Saintes C, Saint-Jean M, Brocard A, Peuvrel L, Renaut JJ, Khammari A, Quéreux G, Dréno B. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib. J Eur Acad Dermatol Venereol 2014; 29:1006-9. [PMID: 24980899 DOI: 10.1111/jdv.12526] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2014] [Accepted: 03/17/2014] [Indexed: 01/12/2023]
Abstract
BACKGROUND Basal cell carcinoma (BCC) is the most common cancer in humans. Vismodegib, a Hedgehog pathway inhibitor, has proved its effectiveness in treating non-resectable advanced BCC. AIM However, its action on squamous cell carcinoma (SCC) is unknown. We present three SCC cases developed into BCC in vismodegib-treated patients. MATERIAL AND METHODS We have described three cases of patients developing SCC during treatment by vismodegib for BCC. RESULTS Patient 1 was treated with vismodegib for five facial BCC. Due to the progression of one of the lesions at month 3 (M3), a biopsy was performed and showed SCC. Patient 2 was treated with vismodegib for a large facial BCC. A biopsy was performed at M2 on a BCC area not responding to treatment and showed SCC. Patient 3 was treated with vismodegib for a BCC on the nose. Due to vismodegib ineffectiveness, a biopsy was performed and showed SCC. DISCUSSION Two similar cases have been described in the literature. This could be due to the appearance of the squamous contingent of a metatypical BCC or to the squamous differentiation of stem cells through inhibition of the hedgehog pathway. CONCLUSION In practice, any dissociated response of a BCC to vismodegib should be biopsied.
Collapse
Affiliation(s)
- C Saintes
- Skin Cancer Unit, CHU Hôtel Dieu, Nantes, France
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Saint-Jean M, Quereux G, Nguyen JM, Peuvrel L, Brocard A, Vallee A, Knol AC, Khammari A, Denis MG, Dréno B. Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. Oncol Rep 2014; 32:808-14. [PMID: 24926836 DOI: 10.3892/or.2014.3265] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Accepted: 03/26/2014] [Indexed: 11/06/2022] Open
Abstract
The relationship between BRAF mutations and the patient clinical profile is still under question. The objective of the present study was to correlate the BRAF mutation status in primary and metastatic melanomas with the clinicopathological profile, disease-free (DFS) and overall survival (OS). A total of 367 melanoma samples from 278 patients were screened for their BRAF status using a combination of allele-specific amplification and DNA sequencing. Two or three tissue samples from the same patient were available for 74 patients. The clinicopathological characteristics were tested for their association with the BRAF mutation using the Fisher's or Pearson's χ2 test. Log-rank tests and Cox models were used for survival analyses. BRAF mutation was found in 152 samples (41.4%). Ten of the 74 patients with several tissue samples (13.5%) had discordant BRAF mutation results. BRAF-mutated patients were significantly younger at the time of primary melanoma and first diagnosis of metastasis than BRAF wild-type patients but with no difference in DFS and OS. According to our results, a primary melanoma with BRAF mutation is not associated with a more aggressive illness.
Collapse
Affiliation(s)
- Melanie Saint-Jean
- Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France
| | - Gaëlle Quereux
- Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France
| | | | - Lucie Peuvrel
- Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France
| | - Anabelle Brocard
- Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France
| | - Audrey Vallee
- Department of Biochemistry, University Hospital Hôtel-Dieu, Nantes, France
| | | | - Amir Khammari
- Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France
| | - Marc G Denis
- Department of Biochemistry, University Hospital Hôtel-Dieu, Nantes, France
| | - Brigitte Dréno
- Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France
| |
Collapse
|
30
|
Peuvrel L, Saint-Jean M, Quereux G, Brocard A, Khammari A, Knol AC, Dreno B. Incidence and characteristics of melanoma brain metastases appearing during vemurafenib treatment. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.9042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Lucie Peuvrel
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Melanie Saint-Jean
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Gaelle Quereux
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Anabelle Brocard
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Amir Khammari
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Anne-Chantal Knol
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | | |
Collapse
|
31
|
Denis MG, Khammari A, Vallee A, NGuyen JM, Knol AC, Saint-Jean M, Peuvrel L, Brocard A, Quereux G, Dreno B. Detection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiency. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.9069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Marc G. Denis
- Department of Biochemistry, Nantes University Hospital, Nantes, France
| | - Amir Khammari
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Audrey Vallee
- Department of Biochemistry, Nantes University Hospital, Nantes, France
| | | | - Anne-Chantal Knol
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Melanie Saint-Jean
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Lucie Peuvrel
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Anabelle Brocard
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Gaelle Quereux
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | | |
Collapse
|
32
|
Denis MG, Knol AC, Vallee A, Khammari A, Caillon H, Saint-Jean M, Peuvrel L, Brocard A, Quereux G, Dreno B. BRAF mutation in circulating DNA of melanoma patients at baseline and intertumor heterogeneity. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.9017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Marc G. Denis
- Department of Biochemistry, Nantes University Hospital, Nantes, France
| | - Anne-Chantal Knol
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Audrey Vallee
- Department of Biochemistry, Nantes University Hospital, Nantes, France
| | - Amir Khammari
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Helene Caillon
- Department of Biochemistry, Nantes University Hospital, Nantes, France
| | - Melanie Saint-Jean
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Lucie Peuvrel
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Anabelle Brocard
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | - Gaelle Quereux
- Dermato-Cancerology department, Nantes University Hospital, Nantes, France
| | | |
Collapse
|
33
|
Saint-Jean M, Quéreux G, Nguyen JM, Peuvrel L, Brocard A, Vallée A, Knol AC, Khammari A, Denis MG, Dréno B. Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy? J Invest Dermatol 2014; 134:1468-1470. [DOI: 10.1038/jid.2013.378] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
34
|
Saint-Jean M, Brocard A, Quereux G, Nguyen JM, Peuvrel L, Knol AC, Khammari A, Denis M, Dréno B. Efficacité du vemurafenib chez deux patients atteints de mélanome métastatique BRAF discordant. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Quereux G, Saint-Jean M, Brocard A, Peuvrel L, Renaut JJ, Dréno B. Efficacité spectaculaire du brentuximab vedotin dans deux cas de lymphome cutané T épidermotrope en impasse thérapeutique. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Le Moigne M, Saint-Jean M, Jirka A, Quéreux G, Peuvrel L, Brocard A, Khammari A, Darmaun D, Dréno B. Dysgueusie et perte de poids sous vismodegib : intérêt d’une prise en charge nutritionnelle spécifique. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
37
|
Quéreux G, Brocard A, Saint-Jean M, Peuvrel L, Knol AC, Allix R, Khammari A, Renaut JJ, Dréno B. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. J Am Acad Dermatol 2013; 69:890-7. [PMID: 24041738 DOI: 10.1016/j.jaad.2013.07.047] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Revised: 07/05/2013] [Accepted: 07/10/2013] [Indexed: 10/26/2022]
Abstract
BACKGROUND Publications reporting photodynamic therapy (PDT) in mycosis fungoides (MF) are rare, involve small samples, and are difficult to compare because of a lack of technical standardization. OBJECTIVE We sought to assess PDT effectiveness and tolerability in early-stage MF using a strict reproducible procedure. METHODS This was a prospective study conducted in Nantes University Hospital, France, including patients older than 18 years with histologically proven MF (stage IA or IB). Methyl-aminolevulinic acid-PDT sessions were repeated monthly for 6 months. Clinical and histologic responses were assessed 1 month after the last session. Patient satisfaction was assessed by telephone survey. RESULTS Twelve patients (with 29 lesions) were treated with PDT. An objective response in target lesions was obtained in 75% of patients. Response rates were similar between plaques and patches but higher in sun-protected compared with sun-exposed areas (trend without reaching significance). During PDT, new lesions appeared in 5 of 12 patients in untreated areas. Most patients were highly satisfied and preferred PDT to the topical chemotherapy previously used. LIMITATIONS PDT procedure criteria selection was partially arbitrary. CONCLUSIONS In early-stage MF, PDT is effective and appreciated (especially when compared with conventional topical chemotherapy). Unilesional and paucilesional forms and lesions in sun-protected areas are to be preferred.
Collapse
Affiliation(s)
- Gaelle Quéreux
- Skin Cancer Unit, Nantes University Hospital, Nantes, France
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Leloup P, Nguyen JM, Quéreux G, Saint-Jean M, Peuvrel L, Brocard A, Dréno B. Predictive value of T-cell clone and CD13 antigen in parapsoriasis. J Eur Acad Dermatol Venereol 2013; 28:518-20. [PMID: 23859066 DOI: 10.1111/jdv.12212] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2013] [Accepted: 06/12/2013] [Indexed: 11/29/2022]
Affiliation(s)
- P Leloup
- Department of Skin Oncology, University Hospital, Nantes, France
| | | | | | | | | | | | | |
Collapse
|
39
|
Quéreux G, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Dréno B. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Expert Opin Pharmacother 2013; 14:1711-21. [PMID: 23837676 DOI: 10.1517/14656566.2013.810718] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Bexarotene was approved for cutaneous T-cell lymphoma (CTCL) in 1999. Apart from the two first clinical trials published ten years ago, very few data were published on the long-term use of bexarotene in CTCL patients. OBJECTIVES We performed a retrospective review of CTCL patients treated with bexarotene at a single skin Cancer department between 2002 and 2012. We aimed to determine retrospectively the long-term tolerability and outcome of bexarotene in a cohort of CTCL patients and to compare these results with data from the literature. RESULTS Thirty-two patients were included (18 men/14 women); 20 patients had a mycosis fungoïdes and 12 a Sézary syndrome. The longest bexarotene treatment duration observed was 65.2 months and 10 patients were treated for more than 24 months. A clinical response was reported in 60% of all patients and in 75% of patients with Sézary syndrome. Most common drug-related adverse events were hypothyroidism (94%), hypertriglyceridemia (78%) and hypercholesterolemia (44%). Most events (84%) were mild to moderate. CONCLUSIONS This study with a very long observation time confirms that bexarotene is well tolerated by CTCL patients during long-term use. It is effective in early and advanced stages of CTCL.
Collapse
Affiliation(s)
- Gaëlle Quéreux
- Nantes University Hospital, Skin Cancer Unit, INSERM 892, 1 Place Alexis Ricordeau 44093, Nantes Cedex, France
| | | | | | | | | | | |
Collapse
|
40
|
Peuvrel L, Chiffoleau A, Quéreux G, Brocard A, Saint-Jean M, Batz A, Jolliet P, Dréno B. Melanoma and rituximab: an incidental association? Dermatology 2013; 226:274-8. [PMID: 23941917 DOI: 10.1159/000350681] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2012] [Accepted: 03/11/2013] [Indexed: 11/19/2022] Open
Abstract
Rituximab is an anti-CD20 monoclonal antibody increasingly used in haematology and rheumatology, but also in internal medicine and dermatology. It has a good tolerance profile without known increased risk of cancer. We report a case of nodular melanoma with a 4.8 mm Breslow thickness that appeared after 2 years of rituximab in a 45-year-old patient with non-Hodgkin lymphoma. Fifteen additional rituximab-associated melanoma cases in 13 patients have been identified in the literature and in the EudraVigilance database. These patients were treated for various indications and had melanomas, often aggressive, initially diagnosed at a metastatic stage in 31% of cases. Our work raises the question of rituximab accountability in melanoma onset in these immunosuppressed patients. A dermatological monitoring seems necessary in patients treated with rituximab, especially in case of risk factors for melanoma. In case of individual melanoma history, the benefit/risk ratio of initiating rituximab therapy should be carefully assessed.
Collapse
Affiliation(s)
- L Peuvrel
- Department of Dermato-Cancerology, Nantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503, Nantes, France
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Khammari A, Limacher JM, NGuyen JM, Saint-Jean M, Quereux G, Brocard A, Peuvrel L, Knol AC, Saiagh S, Bataille V, Dreno B. Adoptive T-cell therapy combined with intra-lesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e20022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20022 Background: The purpose of this study was to evaluate the feasibility, safety and efficacy of adding intra-tumoral injections of TG1042 (Adenovirus 5 expressing Interferon-γ) to adoptive T cell therapy in patients with advanced stage melanoma. Methods: This was a monocentric phase I/II study. The main inclusion criteria were: stage IIIc/IV melanoma, age 18 to 75, at least one injectable metastasis. Tumor infiltrating lymphocytes (TILs) produced from a surgical biopsy of a lesion were infused on days 1 and 29 followed by IL2 injections (6M UI daily) for 10 days. TG1042 was injected at the dose of 5x1010 viral particles per lesion (in up to 6 lesions) every 2 weeks from day -15 to month 2 and then every month up to month 11 or progression. Primary objective was the safety of the procedure; secondary objectives included response according to RECIST and translational research. Results: Eighteen patients have been included. The TILs production was successful in 16 of them. Minor erythema at the TG1042 injection site as well as minor to moderate flu-like symptoms linked to IL2 injections were the most frequent adverse events observed. No grade 3 or 4 treatment related adverse events was recorded. Among the 13 patients evaluable for tumor response 4 patients (31%) had an overall objective response (2 complete, 2 partial), 1patient had a stable disease and 8 progressed. When considering only the injected lesions 6 (46%) had an objective response (3 complete, 3 partial), 3 had a stable disease and 4 progressed. Distant responses in non-injected lesions were observed for 2 patients. Translational research on cutaneous biopsies before and after injections (3 months) showed an increase of CD8 T lymphocytes, IFN-γ and STAT 1 expression in 3 patients. Conclusions: This study demonstrates that co-delivery of TILs and intra lesional TG1042 is feasible and safe. Stimulation of innate immunity by adenovirus expressing interferon-γ could contribute to reverse the immunotolerant profile of the tumour environment. These results support to further explore combined immunotherapies in the treatment of melanoma. Clinical trial information: NCT01082887.
Collapse
Affiliation(s)
- Amir Khammari
- Oncodermatology Department, Nantes Hospital, Nantes, France
| | | | | | | | - Gaelle Quereux
- Oncodermatology Department, Nantes Hospital, Nantes, France
| | | | - Lucie Peuvrel
- Oncodermatology Department, Nantes Hospital, Nantes, France
| | | | - Soraya Saiagh
- Cell and Gene Therapy Unit (UTCG), Nantes Hospital, Nantes, France
| | | | - Brigitte Dreno
- Oncodermatology Department, Nantes Hospital, Nantes, France
| |
Collapse
|
42
|
Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quéreux G, Dreno B. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J DERMATOL TREAT 2013; 25:424-7. [DOI: 10.3109/09546634.2012.751481] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
43
|
Quereux G, Brocard A, Peuvrel L, Saint-Jean M, Knol AC, Renaut JJ, Khammari A, Dréno B. Traitement du mycosis fongoïde par photothérapie dynamique : étude prospective. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
44
|
Quereux G, Saint-Jean M, Peuvrel L, Brocard A, Renaut JJ, Dréno B. Dix ans de traitement du lymphome cutané T épidermotrope par bexarotène. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Kogge A, Saint-Jean M, Peuvrel L, Knol AC, Brocard A, Dréno B, Quereux G. Efficacité du vorinostat dans les lymphomes cutanés T réfractaires ou récidivant après traitement systémique. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
46
|
Saint-Jean M, Quéreux G, Peuvrel L, Brocard A, Knol AC, Saiag S, Khammari A, Bedane C, Basset-Seguin N, Dréno B. Intérêt du traitement par TILs (Tumor-Infiltrating Lymphocytes) dans le mélanome métastatique. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Peuvrel L, Quéreux G, Saint-Jean M, Brocard A, Dréno B. Bilan à un an d’une consultation dédiée aux effets indésirables cutanés des traitements anticancéreux. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GFL, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367:329-39. [PMID: 22830463 DOI: 10.1056/nejmoa1204166] [Citation(s) in RCA: 385] [Impact Index Per Article: 32.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Transplant recipients in whom cutaneous squamous-cell carcinomas develop are at high risk for multiple subsequent skin cancers. Whether sirolimus is useful in the prevention of secondary skin cancer has not been assessed. METHODS In this multicenter trial, we randomly assigned transplant recipients who were taking calcineurin inhibitors and had at least one cutaneous squamous-cell carcinoma either to receive sirolimus as a substitute for calcineurin inhibitors (in 64 patients) or to maintain their initial treatment (in 56). The primary end point was survival free of squamous-cell carcinoma at 2 years. Secondary end points included the time until the onset of new squamous-cell carcinomas, occurrence of other skin tumors, graft function, and problems with sirolimus. RESULTS Survival free of cutaneous squamous-cell carcinoma was significantly longer in the sirolimus group than in the calcineurin-inhibitor group. Overall, new squamous-cell carcinomas developed in 14 patients (22%) in the sirolimus group (6 after withdrawal of sirolimus) and in 22 (39%) in the calcineurin-inhibitor group (median time until onset, 15 vs. 7 months; P=0.02), with a relative risk in the sirolimus group of 0.56 (95% confidence interval, 0.32 to 0.98). There were 60 serious adverse events in the sirolimus group, as compared with 14 such events in the calcineurin-inhibitor group (average, 0.938 vs. 0.250). There were twice as many serious adverse events in patients who had been converted to sirolimus with rapid protocols as in those with progressive protocols. In the sirolimus group, 23% of patients discontinued the drug because of adverse events. Graft function remained stable in the two study groups. CONCLUSIONS Switching from calcineurin inhibitors to sirolimus had an antitumoral effect among kidney-transplant recipients with previous squamous-cell carcinoma. These observations may have implications concerning immunosuppressive treatment of patients with cutaneous squamous-cell carcinomas. (Funded by Hospices Civils de Lyon and others; TUMORAPA ClinicalTrials.gov number, NCT00133887.).
Collapse
Affiliation(s)
- Sylvie Euvrard
- Department of Dermatology, Hospices Civils de Lyon, Edouard Herriot Hospital Group, Lyon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Khammari A, Limacher JM, NGuyen JM, Quereux G, Brocard A, Peuvrel L, Knol AC, Saiagh S, Bataille V, Dreno B. Intra-lesional administrations of TG1042 (adenovirus expressing interferon-γ) combined with adoptive TIL transfer in patients with metastatic melanoma. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e19019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19019 Background: Several tumour factors limit the efficacy of spontaneous immune responses. By changing the tumour environment through immune-stimulation, responses could be more efficient. Methods: This is a phase I/II open, monocentric study with a sample size of 12 patients. The main inclusion criteria were: age 18 to 75, melanoma stage IIIc/IV with cutaneous and visceral metastases except brain metastases. Patients received intra-lesional injections TG1042 combined with tumor infiltrating lymphocytes (TILs) infusions and interleukine-2 (IL2) sub-cutaneous injections. TILs were infused on days 1 and 29 followed by IL2 injections (6M UI daily) for 10 days. TG1042 was injected at the dose of 5x1010 viral particles per lesion (in up to 6 lesions) every two weeks from day -15 to month 2 and then every month up to month 11 or progression. The main objectives were to evaluate the clinical response and safety. Results: Twelve patients stage IVa-c AJCC have been included. Three patients progressed rapidly before starting any treatment and for 2 others TILs were not obtained due to insufficient tumor tissue. Minor erythema at the TG1042 injection site as well as minor to moderate flu-like symptoms linked to IL2 injections was observed. No grade 3 or 4 treatment related adverse events were reported. Among the 7 patients evaluable for tumor response (RECIST rules), 2 partial and 2 complete responses were observed. Distant responses were also observed for 2 patients. Immunohistochemical analysis on biopsies from an injected lesion of 3 patients before and after 3 months of treatment showed an increase of CD8 T lymphocytes in 2 patients with clinical response associated with an increase of IFN-γ and STAT 1 expression. Conclusions: Results of this study demonstrate that TILs-based adoptive cell therapy combined with intra-lesional immunostimulation induced by TG1042 is feasible, safe and can induce a disease control in a majority of patients. Stimulation of innate immunity by adenovirus expressing interferon gamma seems able to reverse the tolerance state within the tumour environment, thus making TILs able to exercise their cytotoxic activity against melanoma.
Collapse
Affiliation(s)
- Amir Khammari
- Oncodermatology Department, Nantes Hospital, Nantes, France
| | | | | | - Gaelle Quereux
- Oncodermatology Department, Nantes Hospital, Nantes, France
| | | | - Lucie Peuvrel
- Oncodermatology Department, Nantes Hospital, Nantes, France
| | | | - Soraya Saiagh
- Cell and Gene Therapy Unit (UTCG), Nantes Hospital, Nantes, France
| | | | - Brigitte Dreno
- Oncodermatology Department, Nantes Hospital, Nantes, France
| |
Collapse
|
50
|
Robert T, Talarmin JP, Leterrier M, Cassagnau E, Le Pape P, Danner-Boucher I, Malard O, Brocard A, Gay-Andrieu F, Miegeville M, Morio F. Phaeohyphomycosis due to Alternaria infectoria: a single-center experience with utility of PCR for diagnosis and species identification. Med Mycol 2012; 50:594-600. [PMID: 22404860 DOI: 10.3109/13693786.2012.663508] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The term phaeohyphomycosis refers to a rare group of fungal infections characterized by the presence of dark-walled hyphae or yeast-like cells in affected tissues. Herein, we report on the clinical and epidemiological characteristics of six cases of phaeohyphomycosis due to Alternaria spp. that occurred in our hospital over a 30-month period (from January 2008 to June 2010). Interestingly, whereas histopathological examinations were positive and fungal cultures yielded molds in all cases, mycological identification using conventional phenotypic methods was never possible despite prolonged incubation of the isolates. Identification of Alternaria infectoria species complex was obtained for each isolate by amplification and sequencing of the internal transcribed spacer of the ribosomal DNA (ITS rDNA). All patients had favourable outcomes following the introduction of azole-based antifungal therapy. This case series describes the clinical course of these six patients and highlights the utility of molecular identification to help in the identification of the etiologic agent when classical mycological methods have failed.
Collapse
Affiliation(s)
- Tiphaine Robert
- Laboratoire de Parasitologie-Mycologie, Centre Hospitalo-Universitaire de Nantes, Hôtel Dieu, Nantes, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|